Ibogalogs decrease neuropathic pain in mice through a mechanism involving crosstalk between 5-HT_2A and mGlu₂...

Area of Science:

• Neuroscience
• Pharmacology
• Pain Research

Background:

• Neuropathic pain is a debilitating condition with limited treatment options.
• Ibogalogs are a class of compounds with potential therapeutic applications.
• The interaction between serotonin 5-HT2A and mGlu2 receptors in pain modulation is not fully understood.

Purpose of the Study:

• To evaluate the anti-neuropathic effects of various ibogalogs in a mouse model.
• To investigate the involvement of 5-HT2A and mGlu2 receptors in the ibogalogs' activity.
• To explore potential crosstalk between 5-HT2A and mGlu2 receptors.

Main Methods:

• Utilized the oxaliplatin-induced neuropathic pain model in mice.
• Assessed pain relief using cold plate and paw pressure tests.
• Investigated receptor involvement using specific antagonists (ketanserin) and agonists (LY379268), and functional assays in HEK293 cells.

Main Results:

• All tested ibogalogs (TBG, DM506, IBG, nor-IBG, CAG, PNU-22394) exhibited significant anti-neuropathic activity without toxicity.
• Ibogainalog (IBG) and catharanthalog (CAG) were the most potent; nor-IBG and DM506 showed the longest duration of action.
• Activity was dependent on 5-HT2A and mGlu2 receptor signaling, with evidence of functional crosstalk and increased mGlu2 receptor phosphorylation.

Conclusions:

• Ibogalogs possess significant anti-neuropathic properties.
• The therapeutic effects are mediated through a synergistic mechanism involving both 5-HT2A and mGlu2 receptors.
• This study reveals a novel pathway for neuropathic pain treatment targeting ibogalogs and their receptor interactions.